PM
COYA icon

Prosight Management’s Coya Therapeutics COYA Stock Holding History

Prosight Management’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$995K Sell
170,000
-250,360
-60% -$1.16M 0.17% 35
2026
Q1 		$1.66M Buy
+420,360
New +$1.97M 0.27% 38

Other funds holding COYA

DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Prosight Management's COYA Position: Q2 2026 in Review

Prosight Management reduced its Coya Therapeutics (COYA) stake by 60% in Q2 2026, selling an estimated $1.16M and leaving 170,000 shares worth $995K. The position accounts for 0.17% of the portfolio, ranked #35.

Prosight Management first reported a position in COYA in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.66M in Q1 2026. 54 funds tracked by Wall St. Rank hold COYA as of Q2 2026.

  • Prosight Management held 170,000 shares of Coya Therapeutics worth $995K as of Q2 2026.
  • Prosight Management sold 250,360 Coya Therapeutics shares in Q2 2026, an estimated $1.16M.
  • Coya Therapeutics made up 0.17% of Prosight Management's portfolio in Q2 2026, its #35 holding.
  • Prosight Management first reported a position in Coya Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Prosight Management's Coya Therapeutics position peaked at $1.66M in Q1 2026.
  • 54 funds tracked by Wall St. Rank held Coya Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.